Saumya Shah, MD
Family Medicine · Glastonbury, CTNPI 1770046369
Payments from drug & device makers
Across 227 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$911
- Novo Nordisk$348
- Lilly USA, LLC$221
- Pfizer$198
- AstraZeneca$177
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 75 | $1,352 |
| AbbVie | 57 | $911 |
| Novo Nordisk | 19 | $348 |
| Lilly USA, LLC | 10 | $221 |
| Pfizer | 10 | $198 |
| AstraZeneca | 9 | $177 |
| Astellas Pharma US Inc | 3 | $166 |
| Exact Sciences | 5 | $119 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $88 |
| Boehringer Ingelheim | 4 | $86 |
| Bayer | 3 | $68 |
| Viatris Specialty LLC | 3 | $66 |
| Actelion Pharmaceuticals US, Inc. | 2 | $54 |
| Amgen | 2 | $48 |
| Corcept Therapeutics | 2 | $46 |
| Eisai Inc. | 2 | $43 |
| Madrigal Pharmaceuticals | 1 | $38 |
| Sanofi | 1 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Novartis | 1 | $28 |
| Mylan Specialty L.p. | 1 | $24 |
| Bausch Health US, LLC | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,362 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 21 | $36,643 |
| EliquisApixaban | 41 | $35,106 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $24,889 |
| MyrbetriqMirabegron | 28 | $20,739 |
| OzempicSemaglutide | 13 | $14,286 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $11,781 |
| EntrestoSacubitril/Valsartan | 12 | $7,982 |
| Atorvastatin Calcium | 163 | $1,533 |
| Levothyroxine Sodium | 87 | $1,099 |
| Omeprazole | 35 | $975 |
| Rosuvastatin Calcium | 47 | $739 |
| Gabapentin | 50 | $695 |
| Metoprolol Succinate | 72 | $688 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $643 |
| Tamsulosin Hcl | 52 | $606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $86 | $36,64321 claims |
| PfizerEliquis | $198 | $35,10641 claims |
| GSKTrelegy Ellipta | $1,352 | $24,88929 claims |
| Astellas Pharma US IncMyrbetriq | $166 | $20,73928 claims |
| Novo NordiskOzempic | $348 | $14,28613 claims |
| NovartisEntresto | $28 | $7,98212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $1,09987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Glastonbury
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
- Helar CamposNew London$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.